STAMFORD, Conn., May 14, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced presentations at the International Investigative Dermatology (IID) 2018 Meeting, to be held May 16-19, 2018 in Orlando.
Details for the presentations are as follows:
Oral and Poster Presentation:
| Title: | "Antipruritic effect of the novel kappa opioid receptor agonist CR845” | |
| Date / Time: | Saturday, May 19, 2018, 3:15–5:45 p.m. EDT | |
| Presenter: | Robert H. Spencer, Senior Director, Research & Development, Cara Therapeutics | |
| Poster Presentations: | ||
| Title: | "Measurement of pruritus associated with chronic-kidney disease in hemodialysis patients: a qualitative study of two patient-reported outcome instruments” | |
| Date / Time: | Thursday, May 17, 2018, 11:45 a.m.–1:45 p.m. EDT | |
| Presenter: | Catherine Munera, Head of Biometrics, Cara Therapeutics | |
| Title: | "Psychometric validation and meaningful change threshold of the worst itching intensity numerical rating scale for use in hemodialysis patients with pruritus” | |
| Date / Time: | Saturday, May 19, 2018, 11:45 a.m.–1:45 p.m. EDT | |
| Presenter: | Catherine Munera, Head of Biometrics, Cara Therapeutics |
For information about IID 2018, visit https://iid2018.org.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors (KORs). Cara is developing a novel and proprietary class of product candidates, led by KORSUVATM (CR845/difelikefalin), a first-in-class KOR agonist that targets the body's peripheral nervous system, as well as certain immune cells. In Phase 2 trials, KORSUVA injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) and is currently being investigated in Phase 3 trials in hemodialysis patients with CKD-aP. Additionally, CR845/difelikefalin has demonstrated efficacy in patients with moderate-to-severe pain, without inducing many of the undesirable side effects typically associated with currently available opioid pain therapeutics.
The FDA has conditionally accepted KORSUVATM as the trade name for difelikefalin injection. CR845/difelikefalin is an investigational drug product, and its safety and efficacy have not been fully evaluated by any regulatory authority.
INVESTOR CONTACT:
Michael Schaffzin
Stern Investor Relations
212-362-1200
michael@sternir.com
MEDIA CONTACT:
Annie Starr
6 Degrees
973-415-8838
astarr@6degreespr.com